Videos

Loretta J. Nastoupil, MD, discusses the use of off-the-shelf chimeric antigen receptor T-cell products for the treatment of patients with diffuse large B-cell lymphoma and other cancers.

Benjamin Levy, MD, discusses how the role of immunotherapy has evolved in the treatment landscape of lung cancer and where he sees this research headed in the future.

Ulka Vaishampayan, MD, discusses the findings from the phase 3 CheckMate-9ER study, which demonstrated promising response and survival outcomes with the combination of cabozantinib plus nivolumab as treatment of patients with metastatic renal cell carcinoma compared with sunitinib.

Ghassan K. Abou-Alfa, MD, discusses the therapies being used to treat patients with hepatocellular carcinoma right now.

Shaji K. Kumar, MD, addresses an important unanswered question that remains in the treatment landscape of newly diagnosed multiple myeloma, which is whether 3- or 4-drug regimens should be used in the frontline setting.

Andre Goy, MD, MS, discusses the benefits of working with a pathologist to develop a better understanding of molecular oncology and optimal treatment decisions for patients with lymphomas.

Experts review clinical cases and best practices for managing relapsed/refractory DLBCL.

Natalie I. U. Vokes, MD, discusses the future of predicting how patients will respond to treatment, especially immunotherapy, based on their genomic profile.

Bradley McGregor, MD, discusses the current treatment landscape for patients with advanced or metastatic renal cell carcinoma, which has significantly evolved over the last few years.

Yelena Y. Janjigian, MD, discusses the differences between biomarker testing at academic centers versus community centers for patients with gastric cancer.

Naomi Haas, MD, discusses several areas of interest for the treatment of patients with prostate cancer that are utilizing PSMA, including bispecific T-cell engager antibodies, chimeric antigen receptor T cells, and the lutetium studies.

Paul Boutros, PhD, MBA, discusses the reasons why some patients with prostate cancer have more aggressive disease than others.

Michael Wang, MD, discusses current and upcoming treatments being investigated for patients with mantle cell lymphoma.

Guillermo Garcia-Manero, MD, discusses how the recently approved combination regimen of decitabine and cedazuridine fits into the treatment landscape for patients with myelodysplastic syndromes.